Compare Jones Lang LaSalle Inc (JLL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Summit Therapeutics Inc — how do they compare? Jones Lang LaSalle Inc trades at $299.87 (market cap $13.95B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Jones Lang LaSalle Inc and Summit Therapeutics Inc are close in size by market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Summit Therapeutics Inc for 16 Days on average.
| JLL | SMMT | |
|---|---|---|
Market Cap | $13.95B | $13.71B |
Volume | 457,462 | 6,173,057 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $26.38 |
52-Week Low | $280.16 | $12.43 |
Typical Hold Time | 71 Days | 16 Days |
Enterprise Value | $16.71B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $299.87, up 1.08% today, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $5.26 exceeding the $4.56 estimate. Revenue grew to $26.12B in 2025, and net income margin improved to 3.64%. Recent news highlights acquisitions and financing deals, such as the $406M Trammell Crow Center financing announced on September 24, 2026.
The outlook is positive, supported by analyst consensus price target of $450.50 and 58.33% buy ratings. Key opportunities include growth in data center operations and proprietary platforms, while risks involve real estate market volatility and competitive pressures. The stock offers value with a P/E of 14.54 and P/S of 0.53, but investors should monitor debt levels and economic cycles.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
